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Abstract: The oral mucosa offers an interesting site for the application of dosage forms that release drugs within/throughout the oral mu-
cosa, by assuring a high drug bioavailability for topic and systemic effects. However, the relative permeability of the oral mucosa and the 
washing effect related to the oral fluids and mechanical stresses must be considered in the formulation of oral dosage forms. Since a sus-
tained drug release can be guaranteed only if dosage forms remain in contact with the oral site of absorption/application for a prolonged 
time, the development of mucoadhesive dosage forms is mandatory. The mucoadhesion is a complex phenomenon and the mucoadhesive 
bond consists of two different parts, the mucoadhesive polymers and the mucous substrate. In addition to factors related to the oral mu-
cosa and oral environment features, the physical-chemical characteristics of mucoadhesive polymers must be also considered as factors 
influencing the mucoadhesive bonds. While it is not possible to modify the mucosal features or it is possible to modify or inhibit only in 
part certain mucosal processes, the knowledge of polymer properties influencing mucoadhesive bonds allows to modify or to control 
these properties in developing increasingly effective mucoadhesive systems. The aims of this review are to discuss the several mecha-
nisms and factors behind the phenomenon of mucoadhesion with particular reference to the features of the oral environment, oral mu-
cosa, and polymeric compounds influencing mucoadhesion process. Finally, a brief mention to the main mucoadhesive dosage forms de-
signed for oral transmucosal drug delivery is made. 
Keywords: Mucoadhesion, oral transmucosal drug delivery, dosage form, drug controlled-release, mucoadhesive polymers, oral mucosa, 
mucosal permeability. 
1. INTRODUCTION 
 The ultra-structural features of the oral mucosa have attracted 
increasing attention due to its potential use for the systemi-
cally/topically delivery of biologically-active drugs, which possess 
high pharmacological efficacy with site-specificity; to date, these 
drugs cannot be administrated through an effective, safe, and non-
invasive route. Oral transmucosal drug delivery is growing as a 
feasible alternative to conventional (peroral and parenteral) routes 
as it offers many advantages. Unlike the peroral route, it avoids the 
gastric hydrolysis and hepatic first-pass effect and hence it provides 
an improved bioavailability, lower drug doses and less dose-related 
side effects [1, 2]. Since the parenteral route is more invasive, often 
requiring numerous injections due to the short half-life of certain 
drugs and is not free from complications as anaphylaxis, blood 
extravasation and infections, oral transmucosal drug delivery en-
sures a safe, not invasive route with a better patient compliance, 
especially during medium- and long-term chronic therapy. In addi-
tion, the oral mucosa offers some clear advantages over other 
transmucosal (ocular, nasal, pulmonary, rectal and vaginal) and 
transdermal administration routes [3]. In fact, among all the trans-
mucosal sites, the oral mucosa is more easily accessible and is 
highly vascularized, allowing a direct access to the systemic circu-
lation by-passing the liver first-pass effect with consequent high 
bioavailability and acceptability by the patient [4]. Moreover, as 
being characterized by a rapid cellular turnover, the oral mucosa is 
less susceptible to damage or irritation potentially related to the 
drug or the excipients loaded in the dosage forms [5]. Finally, the 
relative absence of peptidases and/or the possibilities to use enzyme 
inhibitors as excipients in the dosage forms makes the oral mucosa 
a promising route for the systemic delivery of macromolecular 
drugs (peptides and proteins) [6]. Nevertheless, the oral transmu-
cosal route has some disadvantages mainly related to the low  
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permeability of the mucosal membrane and to the physiological 
mechanisms, as washing effect or saliva and mechanical stresses, 
which cause short retention times of the conventional dosage forms 
since they are quickly removed from the site of application/ absorp-
tion [7].  
 These limitations can be overcome by developing of bioadhe-
sive dosage forms. Various administration routes, such as ocular, 
nasal, buccal and gingival, gastrointestinal, vaginal and rectal, are 
based on mucoadhesive drug delivery systems [8]. 
 The advantages associated with the use of mucoadhesives in 
drug delivery include: i) an intimate and prolonged contact with the 
site of absorption for an increased retention time without interfering 
with the physiological activities such as eating, drinking and talk-
ing; ii) an improved drug bioavailability; iii) a reduced administra-
tion frequency; iv) a simplified administration of a dosage form and 
v) termination of a therapy as well as the possibility of targeting 
particular body sites and tissues [9]. The mucoadhesion is achieved 
through the use of special polymers that allow the binding to the 
mucin layer of biological membranes. These polymers should have 
some basic requirements, such as anionic hydrophilia with hydro-
gen groups, a sufficient flexibility and wetting and spreading capa-
bility to the mucus network surface and to the tissues crevices [10].  
 In addition, chemical permeation enhancers, enzyme inhibitors 
or pH modifiers may be included as excipients in several dosage 
forms in order to warrant the release of a correct therapeutic dose of 
medication, either locally or systemically, at a fixed rate in a spe-
cific site of action/absorption [11]. Finally, during the formulation 
design of new delivery systems, the possibility, by combining two 
or more mucoadhesive polymers, to formulate devices for issuing 
multi-directional or unidirectional drug release, depending on 
therapeutic needs, must also be considered [12].  
 The aims of this review are to discuss the several mechanisms 
and factors behind the phenomenon of mucoadhesion with particu-
lar reference to the features of the oral environment, oral mucosa, 
and polymeric compounds influencing mucoadhesion process. Fi-
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nally, a brief mention to the main mucoadhesive dosage forms de-
signed for oral transmucosal drug delivery is made. 
2. ORAL MUCOSA AND ORAL ENVIRONMENT 
 Although extensively discussed in other publications [12-16], 
the knowledge of anatomical, histological and physiological fea-
tures of the oral mucosa as well as those of the main factors belong-
ing to the oral environment (i.e. mucus, saliva) which may affect 
the mechanisms of bioadhesion on mucosal surface must be consid-
ered a starting point to better understand the phenomenon of muco-
adhesion.  
2.1. Oral Mucosa: Histology, Physiology and Permeability Fea-
tures 
 The oral cavity must be considered as a unique structure that 
extends from vermilion of the lips anteriorly, to the isthmus of the 
mouth posteriorly and includes the lips, cheeks, tongue, hard and 
soft palate and the floor of the mouth. The oral cavity, like other 
body cavities that communicate with the external world, is covered 
by a biological membrane called oral mucosa, coated by mucus or 
serous secretions.  
 The oral mucosa has a total surface area of about 200 cm and 
shows differences in structure, thickness and blood flow depending 
on their location within the oral cavity [17]. Both histologically and 
functionally it consists of two layers, one of mesodermal origin 
(lamina propria) and the epithelial one, connected by a proteina-
ceous fibrous extracellular matrix thickness called basal lamina or 
basement membrane [18] (Fig. 1a). This structure constitutes a 
distinct layer from the epithelial and connective tissues, but is 
closely linked to them; in fact it provides a mechanical support to 
the overlying epithelium and permits its connection to the underly-
ing lamina propria. The basement membrane with a thickness of 
about 1-2 m acts as barrier to permeability only marginally, limit-
ing the diffusion of certain molecules (such as complexes) from and 
to the epithelium [19]. Furthermore, the surface charge of its mole-
cules may impede and/or limit the penetration of lipophilic mole-
cules which have just passed the epithelial layer relatively easily 
[20]. 
 The lamina propria provides many of the mechanical properties 
of the oral mucosa and the blood supply essential for the epithelial 
tropism; it also allows the passage of molecules (included the 
drugs) in the systemic circulation (see below), one of the main as-
pect in the oral drug delivery. Since its structure is insufficiently 
dense it not usually acts as a barrier also to relatively large mole-
cules; furthermore, its hydrated matrix may facilitate the passage of 
hydrophilic compounds [4]. 
 The stratified squamous epithelium consists of differentiating 
layers of cells (keratinocytes) which change in size, shape, and 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). a) A schematic representation of the structure of the oral mucosa with special details (b) for the oral epithelium layers. MCGs become apparent in the 
upper part of the spinous layer (b); c) this table shows differences in the degree of keratinization, thickness and permeability features between the oral different 
sites. 
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content as they travel from the basal region to the superficial re-
gion, where the cells are shed (Fig. 1b). The epithelium of the oral 
mucosa is about 40-50 cell layers thick [15], even if the thickness of 
oral mucosa varies depending on the site: the buccal mucosa and 
the dorsal tongue measures 500-800 m, while the epithelial thick-
ness of the hard and soft palates, the floor of the mouth, the ventral 
tongue, and the gingivae are about 100-300 m [15] (Fig. 1c). Oral 
squamous stratified epithelium is divided into non-keratinized and 
keratinized epithelium. The differentiation processes that occur in 
keratinized and non-keratinized epithelia differ significantly, and 
this results in either the presence or absence of a cornified surface 
layer [21]. 
 The structure of the oral mucosa varies according to functional 
adaptations between the different regions of the oral cavity. It is 
noteworthy that there are three different types of oral mucosa 
within the oral cavity [22-25]: masticatory mucosa (i.e. gingivae 
and hard palate), specialized mucosa (i.e. dorsum of tongue) and 
lining mucosa (e.g. buccal mucosa and floor of mouth). From 
measurements made by Collins and Dawes [17], these represent 
approximately 25%, 15% and 60% of the oral mucosa, respectively. 
The oral mucosa subjected to mechanical stress such as gingivae 
and hard palate is keratinized similar to the epidermis. The epithe-
lium of the lining mucosa covers the remaining regions, except the 
dorsal surface of the tongue, and is a non-keratinized one. 
 As discussed above, the oral mucosa is characterized by highly 
compacted epithelial cells, whose primary functions are to protect 
the underlying tissues against fluid loss and from chemical and 
mechanical damages [19]. Nevertheless, it is well known as the oral 
mucosa is 4-4000 times more permeable than the skin [26]. 
 The oral mucosal tissue produce a large amount of extracellular 
material, useful for the epithelial elasticity, lubrication and wettabil-
ity of the cell epithelial surface, for the regulation of its moisture 
content and as a permeability barrier. The cell membrane of outer 
cell layers of non-keratinized epithelia contains lipids as phosphol-
ipids, cholesterol sulphate, ceramide, glucosphingolipid and glyco-
sylceramides which act as a barrier to hydrophilic molecules [27, 
28]. However, the presence of lipids and cytokeratins in the super-
ficial keratinocytes of the non-keratinized epithelia is much less 
marked than in the keratinized ones, making the lining mucosa 
much more permeable, especially to water and hydrophilic mole-
cules, and so more suitable for systemic drug delivery. Whilst the 
outer layer of the epithelium is liphophilic, the interior content of 
the cells is hydrophilic; hence, to obtain an efficient drug delivery, 
drug formulations must be designed in such a way to overcome this 
double barrier, one hydrophobic and one hydrophilic in nature, to 
pass and diffuse through the epithelial tissue and reach the lamina 
propria [29, 30].  
 Furthermore, it is important to underline that the main “barrier 
region” to penetration of molecules across the oral epithelium is 
such due to the intercellular material originated from the “mem-
brane coating granules” (MCGs) [31, 32]. They have been found in 
both non-keratinized and keratinized epithelia, highlighting as the 
keratinisation, alone, cannot act as the main factor against the pene-
tration of molecules [33, 34]. The MCGs are small cytoplasmic 
organelles mainly produced by the Malpighian cells. Their content, 
rich in lipids and glycolipids, is discharged in the extracellular 
spaces covering and linking the cells of the stratum spinosum, 
which contains not flattened cells closely held together by desmo-
somes at various stages of differentiation [35] (Fig. 1b) Here, the 
content of MCGs also acts as a barrier to permeation of various 
molecules [36]. 
 Another barrier to drug permeability across the oral epithelium 
is represented by enzymatic degradation of peptides and proteins. In 
addition to salivary enzymes (see below), several proteolytic en-
zymes are present both within the cell cytoplasm and in the ex-
tracellular matrix [37]. The extracellular enzymes are mainly repre-
sented by aminopeptidases (aminopeptidase A and N – plasma 
membrane bound peptidase) and protease; whilst some intracellular 
peptidase (aminopetidase B – cytosolic peptidase) provide the hy-
drolysis of particular smaller peptides, which penetrate within the 
epithelial cells, in to free amino acids [38]. Unlike the enzymatic 
barrier existing in the small intestine, oral mucosa is less rich of 
peptidase linked to the cell membrane [6], so the peptide drug me-
tabolism occurs mainly in the intracellular environment where they 
are located most of the endopeptidase. It would seem that the en-
zymatic barrier is able to hydrolyse only the drugs that permeate 
through an intracellular pathway, while, due to the low extracellular 
proteolytic activity of the oral epithelium, drugs that follow a 
paracellular route of absorption would be able to avoid this degra-
dation [6, 12]. 
 Since proteolytic enzymes are ubiquitous, the absorption of 
peptide drugs and the action of mucoadhesive polymers in their 
intact forms are virtually impossible, and thus, the use of enzyme 
inhibitors in the dosage forms is needful [6, 12, 39].  
 Despite the above mentioned factors which may interfere with 
the permeability, but as will be shown in this review they can be 
overcome, there are some important aspects which allow to con-
sider the oral mucosa as an innovative site for transmucosal drug 
delivery. Beyond its easy and not invasive accessibility, the two 
main factors for oral drug delivery are the turnover time of epithe-
lial cells and the vascularisation of the lamina propria. The rate of 
turnover is the time for a cell to divide and pass through the entire 
epithelium and, for oral epithelium, falls between those for skin (34 
days) and intestine (4 days) and it has been generically estimated at 
5-6 days [4]. The rate of the epithelial cell proliferation depends on 
different patterns of epithelial maturation: in general, the rate is 
higher for cells in thin non-keratinized regions, such as floor of 
mouth and ventral surface of tongue than for thicker keratinized 
regions, such as palate and gingiva [40]. The high turnover rate is 
an important issue that affects drug absorption, by continually 
changing permeability features, demanding long-term bioadhesion 
of dosage forms for prolonged drug delivery; furthermore, it is im-
portant to underline that the high turnover rate makes the oral mu-
cosa able to promptly reacting to any external insult. Compared to 
other transmucosal sites, oral mucosa is less susceptible to injury or 
damage potentially related to the drug or the excipients loaded into 
the transmucosal dosage forms [41]. 
 The other important factor is the vascularisation of the oral 
mucosa. Thanks to a rich arterial blood supply derived from the 
external carotid artery and its secondary vessels, the oral mucosa, 
although with some differences among the various sites, is a struc-
ture highly vascularised. This aspect is one of the main factors for 
the drug delivery efficiency through the oral cavity. In fact, al-
though the entire surface area of the oral mucosa is smaller than 
that of the skin (20.000 cm
2
) and gastrointestinal tract (350.000 
cm
2
), its high vascularization and the relatively fast blood flow (i.e. 
2.4 ml/min/cm
2
 for the buccal mucosa) facilitates the passive diffu-
sion of drug molecules across the mucosa and their direct access to 
the systemic circulation via venous capillaries which reach the in-
ternal jugular vein, by-passing the gastrointestinal tract and the 
hepatic first-pass metabolism with consequent high drug bioavail-
ability. 
2.2. Absorption Pathways 
 Permeability measurements have suggested that different sub-
stances may permeate oral epithelium at different rates, depending 
on the chemical nature of the molecule and the histological features 
of the tissue being traversed. There are considerable regional differ-
ences in the permeability pattern in oral mucosa. In general, the 
permeability of oral mucosa decreases gradually from the sublin-
gual through to the buccal and palatal mucosa [12]. This rank order 
is related to the relative thickness and degree of keratinization be-
tween these regions: sublingual mucosa is relatively thin and non-
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keratinized, the buccal thicker is non-keratinized, and the palatal is 
intermediate as regards thickness but keratinized [36]. Compounds 
with different chemical properties penetrate the “barrier region” by 
different routes. Substances can be transported across the mucosal 
membrane by passive diffusion, carrier-mediated active transport or 
endocytosis. Two main pathways seem to be implicated in passive 
diffusion across membranous tissues: intra-cellular (or transcellu-
lar) pathway and inter-cellular (or paracellular) pathway. A single 
drug can permeate through the oral mucosa using both routes simul-
taneously but the route offering the least penetration resistance is 
usually preferred, depending on the physicochemical properties of 
the drugs (e.g. size, lipophilia, hydrogen bond potential, charge and 
conformation) [38]. It should be emphasized that the oral mucosa is 
both hydrophilic and lipophilic in nature. While portions of the 
intercellular spaces and cytoplasm are hydrophilic, thereby provid-
ing a permeability barrier to lipophilic compounds due to their low 
solubility, the cell membrane and the intercellular lipids are lipo-
philic and, given their low partition coefficient, they provide a per-
meability barrier to hydrophilic drugs. Although a carrier-mediated 
transport of monocarboxylic acids from rabbit oral mucosa has been 
reported [44], these systems have not been fully described and fur-
ther investigations are warranted.  
 The process of absorption of a drug across the oral mucosa 
occurs principally by a process of passive diffusion. Therefore, 
considering the oral mucosa as a hydrophobic membrane, Fick's 
first law equation can be used to describe the process of absorption 
of a drug [42]. By analysing this equation, there are drug and oral 
mucosa not modifiable parameters, such as diffusion coefficients, 
the partition coefficient, the tissue thickness and adjustable parame-
ters such as surface area available absorption, retention time and 
concentration of the drug, which are features that can be modified 
by the formulation of the dosage form. 
2.3. Oral Environment 
 In addition to the intrinsic features of the oral mucosa, two 
other important factors, as saliva and mucus, belonging to the oral 
environment, play an important role both in transmucosal drug 
delivery and in mucoadhesion. A special attention will be focused 
on mucus and mucins as the knowledge of their composition, struc-
ture and function is crucial for the mechanisms of bioadhesive con-
trolled drug release.  
2.3.1. Saliva 
 Saliva is a fluid mainly composed of water (99.5%), inorganic 
(0.2%) and organic substances (0.3%) [43] which continuously 
wets the whole surface of the oral mucosa creating a thin coating of 
about 70 m [17]. 
 The presence of saliva facilitates the dissolution of the drug 
from the dosage form, but at the same time, when it is swallowed, 
can contribute to its removal from the site of action/absorption. In 
addition, the drug released by the delivery device is not uniformly 
distributed within the saliva so that some areas of the oral cavity 
could not receive therapeutic levels of the drug [44]. The constant 
flow of saliva in the mouth make difficult the application of dosage 
forms able to stay in close contact with the mucosa for a long pe-
riod of time.  
 On the other hand, the continuous hydration of the mucus 
membrane, due to saliva, can greatly facilitate the drug absorption 
improving the mucoadhesion of mucoadhesive delivery systems 
[6].  
 The optimal hydration and moisture status of the oral mucosa is 
guaranteed by the salivary proteins and in particular to some mucin 
glycoproteins. The most important salivary mucin is called MG1 
[45] whose role are: to maintain hydration, to provide lubrication, 
to concentrate protective molecules such as secretory immuno-
globulins, and to limit the attachment of microorganisms. 
 In general, mucins are important not only because provides the 
oral mucosa wettability but mainly for their fundamental role in 
mucoadhesion of the dosage forms (see below).  
 Finally, it must be considered that saliva contains moderate 
levels of some enzymes as esterases, carbohydrases and phospha-
tases that may degrade certain drugs and adhesion polymers, par-
ticipating in the realization of the enzymatic barrier. 
2.3.2. Mucus 
 Mucus is a complex viscous adherent secretion lining the 
epithelial surfaces of the eyes, ears, nose, respiratory, reproductive 
and gastrointestinal tracts, included the oral cavity [46, 47]. 
 Mucus is produced by mucous cells (usually the goblet cells), 
which are common constituents of the lining epithelia of organs and 
apparatuses communicating directly and indirectly with the external 
environment. Instead, in the oral cavity, most of mucus (about 
70%), fundamental to maintain the mucin layer over the oral mu-
cosa, is produced by mucus secreting cells belonging to the sublin-
gual and minor salivary glands [29, 44, 48]. 
 Mucus is primarily composed of water (90%-98%) and mucins 
forming a viscoelastic mixture of (in a smaller proportion, -< 1%) 
proteins, immunoglobulins (secretory IgA), enzymes (lysozyme and 
lactoferrin), lipids, mucopolysaccharides, nucleic acids, cellular 
debris and various ionic species [49].  
 Mucins are hydrophilic and asymmetric glycoproteins with a 
high molecular weight; they are composed by a single chain pro-
tein-based backbone (composed by amino-acids as serine, threonine 
and proline) from which branch off many large oligosaccharide-
based chains (composed by N-acetylgalactosamine, N-acetyl-
glucosamine, galactose, fucose and N-acetylneuramic acid or sialic 
acid). The protein core is heavily glycosylated for about its 63% by 
oligosaccharide chains and shows one o more terminal peptide re-
gions where there is little o none glycosylation.  
 Other than carbohydrates and proteins that constitute the mucin 
structure for the 70%-80% and 12%-25%, respectively, up to 5% of 
ester sulphate have been founded [50, 51].  
 Each mucin molecule is characterized by an open structure, 
linear and non-linear, organized according a random criteria. 
Thanks to the establishment of both intermolecular non-covalent 
and disulphide bonds, the mucin glycoproteins bind to each other 
forming a highly entangled network of macromolecules that repre-
sent the central structure of the mucus and is responsible for its 
rheological properties [49]. The heavily glycosylation of mucins 
related to their dense oligosaccharide-based coating makes mucin 
network able to retain water, imparting a gel-like property to mucus 
and a resistance to proteolysis [29]. 
 When the environmental pH is near neutral, as in the oral cavity 
in which it oscillates from 6.2 to 7.4, the presence of sulphate 
groups associated to carboxylate groups (sialic acid) at the terminus 
of some sugar units renders mucins to be molecules with a negative 
charge and then they behave as an anionic polyelectrolyte; this may 
play a role in mucoadhesion [49, 52]. Hence, at physiological pH, 
mucus can form a highly cohesive gel structure that binds to the 
epithelial surface, forming a gelatinous layer [53] which associated 
to its resistance to proteolysis may contribute to maintain the barrier 
properties of oral mucosa [25].  
 Because of the numerous anionic and cationic functional groups 
of mucins, the electronically charged molecules may interact, by 
means of electrostatic attractions, hydrogen bonds or hydrophobic 
interactions, with some environmental molecules, included drugs, 
obstructing their transport throughout the epithelium [6, 54].  
 Mucus is a dynamic system, generated continuously by mucus 
cells, having a short clearance period, a relatively fast turnover time 
(that influence mucoadhesion) and whose secretion may be stimu-
lated by toxic and irritating stimuli in order to form a thick layer 
and so to remove irritants from the epithelium [52]. However, it is 
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important to underline that the barrier determined by the mucus 
layer is negligible compared to other barriers that molecules en-
counter during their passage through the oral mucosa [6]. Mucus 
layer is an efficient semi-permeable barrier system allowing the 
diffusion of selected small molecules (water, nutrients) and ions; 
whilst it remains impermeable to the most pathogenic microorgan-
isms and also to the diffusion of many large drug molecules and 
nanomedicines [54]. 
 Despite the possibility that the mucus layer interferes with the 
absorption of drugs, its presence can be beneficial for preparing 
bioadhesive transmucosal drug delivery systems. 
3. DRUG DELIVERY VIA THE ORAL MUCOSA  
 Considering the above described features of the oral mucosa 
and the complexity of the oral environment, it is easily understood 
that it is feasible using the oral mucosa as a site for oral transmu-
cosal delivery, but, at the same time, there are many parameters to 
consider for a successful formulation of oral transmucosal dosage 
systems. 
 Briefly, drug delivery via the oral mucosa can be subdivided 
into two different approaches: drug delivery via the keratinized 
mucosae and drug delivery via the non-keratinized mucosae (Fig. 
2). The selection of an approach over another mainly depends on 
regional differences in terms of anatomical and permeability fea-
tures, which exist among these oral mucosal sites [5]. The kerati-
nized mucosae, such as gingival and hard palatal mucosae, are not 
still considered a valid site for systemic administration of drugs and 
they should be considered as useful sites for local drug delivery in 
the treatment of oral diseases with gingival or palatal location. In 
particular, rationale behind gingival drug delivery is that concen-
trated amounts of active medications can be delivered to the precise 
site of the disease process with minimal systemic uptake of the 
medication [55]. Such kind of devices could be useful adjuncts to 
conventional mechanical therapy and are related to low side effects 
and drug interactions.  
 Drug delivery via the not keratinized mucosae can be subdi-
vided into two approaches: sublingual drug delivery, which is sys-
temic delivery of drugs across mucosa lining the floor of mouth; 
buccal drug delivery, mainly via the buccal mucosa lining the 
cheeks, includes systemic and/or local delivery. The sublingual 
mucosa is more permeable and thinner than the buccal mucosa, 
making it a feasible site if a rapid onset is desired [15]. Thus, the 
sublingual route is generally used for the systemic delivery of drugs 
in the treatment of acute disorders. The buccal mucosa is consid-
erably less permeable than sublingual mucosa and it is unable to 
provide the rapid onset of absorption observed with sublingual ad-
ministration [4]. Furthermore, the lower permeability of this region 
and the presence of smooth muscle and relatively immobile mucosa 
make buccal mucosa a preferred route for the systemic treatment of 
chronic disorders when the sustained release of systemically-acting 
drugs, by means of mucoadhesive delivery systems, is required, 
thereby overcoming the drawbacks when administered by conven-
tional routes [56]. 
 Oral local drug delivery is a more efficient drug delivery ap-
proach than systemic delivery for the treatment of oral conditions. 
The reason for the large interest in the local treatment of the oral 
cavity diseases is a result of their being amongst the most prevalent 
in humankind. Several different types of oral cavity disorders exist, 
such as oral candidiasis, gingivitis, xerostomia, dental caries, acute 
and chronic oral lesions which could be treated locally without the 
need for ingestion and systemic distribution of drugs. Traditional 
treatments of oral diseases are extremely costly in most industrial-
ized countries, according to the World Health Organization. Many 
oral diseases are chronic and, hence, require chronic treatment 
regimens [57]. Local drug delivery provides a more targeted route 
of administration as smaller amounts of drug can be easily targeted 
to the not healthy site, thereby reducing side effects. On the basis of 
these considerations, local drug delivery should be considered a 
delivery route appropriate for drugs exhibiting high therapeutic 
potency as relatively small quantities of drugs can be delivered 
directly onto the oral lesion [58]. 
 Unfortunately, when administered in both local and systemic 
within/throughout the oral mucosa, conventional dosage forms have 
not been effective in ensuring adequate therapeutic levels of drugs 
at the site of action/absorption. The main disadvantage is the low 
bioavailability depending on the physiological removal mechanisms 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Drug delivery via the oral mucosa may occur in different ways according to the degree of keratinization of the oral sites. Generally, keratinized areas 
offer a certain resistance to the drug absorption and thus they can be used only for the topical treatment of oral diseases. The not keratinized sites instead can 
be used also for the systemic release of drug, whose more or less onset of action depends on the degree of vascularization of the oral site of absorption. 
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of the oral cavity (washing effect of saliva and mechanical stress). 
These dosage forms are constantly washed away, resulting in a too 
short retention time, unpredictable distribution of the drug on the 
site of action/absorption and an initial burst effect followed by a 
rapid decrease in concentrations to below therapeutic levels [12].  
 To overcome these problems, dosage forms should have in their 
formulation: 
1. Mucoadhesive polymers, in order to provide an intimate and 
prolonged contact with the absorption site; 
2. chemical penetration enhancers, in order to improve drug per-
meation across oral mucosa or drug penetration into the deep-
est layers of the epithelium, according to the therapeutic needs 
(systemic or local drug delivery); 
3. enzymatic inhibitors, in order to eventually protect drugs from 
the enzymatic degradation. 
 For these reasons, new “attached” (better defined as adhesive) 
drug delivery systems for the local drug delivery have been devel-
oped [59]. Recent research on polymers with mucoadhesive proper-
ties has led to the development of several buccal delivery systems 
able to maintain a steady release of drug in the systemic circulation 
thanks to a closed contact with the mucosal membrane, resulting in 
high concentration in a local area and high drug flux through the 
mucosa [11-15, 33-41]. Because the transient spikes in drug con-
centration, typical in a daily multiple-dose regimen, are not present 
with these delivery systems, the risk of toxic side-effects is de-
creased [57]. 
4. ADHESION PROCESS  
 The term adhesion indicates the fixing of two surfaces together. 
If the environment, in which this union takes place, is biological in 
nature, the term “bioadhesion” should be preferred. In pharmaceuti-
cal science, the bioadhesion refers to the adhesion of a polymeric 
delivery system to a biological surface [60]. Instead, the term “mu-
coadhesion” must be preferred if an intimate contact between the 
mucosal surface, covered with mucus, and a polymer occurs [61]. 
The mucoadhesion is a complex phenomenon and the mechanisms 
by which a polymer adheres to the mucosal surface are not fully 
understood.  
 The term polymer indicates long macromolecules consisting of 
structural subunits and repeating subunits linked by covalent bonds. 
These subunits, called monomers, are low-medium molecular 
weight molecules that connect with each other during polymeriza-
tion process, giving rise to macromolecules with new chemical and 
physical characteristics [29]. The adhesive polymers represent a 
large family of molecules which are generally used in the formula-
tion of mucoadhesive dosage forms in order to form an adhesive 
bond with the biological structures thanks to the mucoadhesive 
features of these macromolecules. 
 To explain the mucoadhesion phenomenon, five different theo-
ries have been proposed, but it is likely that all these theories must 
be considered as different phases of a single process characterized 
by multiple steps of interaction between the two substrates, rather 
than as individual and different theories [8, 49, 52]. 
4.1. Absorption Theory 
 This theory states that the adhesion is the result of the formation 
of interfacial chemical (primary and secondary) bonds between the 
mucoadhesive polymer and the mucus substrate. The secondary 
chemical bonds such as hydrogen bonds and electrostatic interac-
tions are the most desirable in the formulation of adhesive systems, 
since they have the advantage of being semi-permanent, while the 
primary chemical bonds, as covalent, metallic and ionic, may cause 
irreversible damage of the due to their permanent features [62]. 
 
 
4.2. Electronic Theory 
 This theory is based on the transfer of electrons due to the dif-
ferent electrical properties of the mucus and the mucoadhesive 
polymer. The electron transfer involves the formation of a double 
layer of charges and consequently electrostatic attractive forces and 
an interdiffusion layer between the two surfaces with opposite 
charges. It is likely that this theory is more relevant in adhesion 
involving polymer and metal substrates. Controversial opinions 
about this theory consider the electrostatic forces only the result of 
an high bond strength rather than a crucial factor in the formation of 
the adhesive bond [63]. 
4.3. Fracture Theory 
 This theory connects the force required to separate the polym-
eric compound from the substrate with the mucoadhesive bond 
strength. The energy required to break this bond was found to be 
greater as the chains of the polymer network are longer and as the 
cross-linking degree of the mucoadhesive system are lower. This 
theory is particularly considered useful to calculate the strength of 
adhesive bond when mucoadhesive solid and rigid materials are 
involved [60]. 
4.4. Wetting Theory 
 This theory is based on the penetration of the adhesive poly-
mers through the mucosal surface irregularities and their subse-
quent anchoring. This theory is mainly applicable to liquid or semi-
solid mucoadhesive systems and basically may be considered as a 
measure of the capability of mucoadhesive systems to wet the mu-
cosal surfaces. The adhesive performance of a liquid or semi-liquid 
adhesive system depends on its wettability. The wettability can be 
defined as the ability of a viscous liquid to maintain contact with a 
solid surface, resulting from intermolecular interactions when the 
two are brought together. The degree of wetting (wettability) is 
determined by a force balance between adhesive and cohesive 
forces. Regardless of the amount of wetting, the shape of a liquid 
drop on the mucosal surface is approximately a truncated sphere. 
Adhesive forces cause a liquid drop to spread across the surface. 
Cohesive forces within the liquid system cause the drop to ball up 
and avoid contact with the surface. The contact angle (), is the 
angle at which the liquid–vapour interface meets the solid–liquid 
interface. The contact angle is determined by the resultant between 
adhesive and cohesive forces. As the tendency of a drop to spread 
out over the mucosal surface increases, the contact angle decreases. 
Thus, the contact angle provides an inverse measure of wettability. 
The polymeric adhesive systems that have structural features and 
functional groups similar to the mucus substrate, have a greater 
miscibility, and thus an higher degree of spreadability on mucosal 
surfaces [63, 64]. 
4.5. Diffusion Theory 
 The theory is based on the concentration gradient- and time-
dependent penetration of the polymer chain of the macromolecules 
in the glycoprotein network of the mucus. This two-way diffusion 
process involves the formation of a layer of interpenetration and the 
strength of the adhesive bond depends on its extension. It is re-
ported that an effective adhesion is usually achieved when the in-
terprenetration layer thickness reaches about 0.2-0.5 m. The extent 
of this layer depends on various factors such as concentration gra-
dient, molecular weight of adhesive macromolecules, their hydro-
dynamic size, their mobility and flexibility. The length of the poly-
mer chains is also an important factor: long polymer chains are 
more able to disseminate and penetrate mucus substrate and it has 
been reported that a chain length of at least 100,000 kDa is neces-
sary to obtain an interprenetration degree suitable for the formation 
of the adhesive bond; on the other hand, an excessive cross-linking 
degree between the polymer chains could result in a reduced mobil-
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ity and therefore decrease the extent of interprenetration layer and 
strength of the adhesive bond [49].  
 The depth of this layer also depends on the contact time re-
ferred as the retention time of the mucoadhesive dosage form on the 
mucosal surface in order to ensure an adequate exposure of contact 
between the surfaces of both polymers. Recently, it was shown that 
the temperature is another important environmental factor in this 
process. 
 A key factor, in obtaining the maximum interdiffusion between 
both polymeric networks and the best strength during the formation 
of the adhesive bond, is that both systems should be miscible with 
each other since they should have similar solubility parameters and 
diffusion coefficients [62]. 
 As above mentioned, none of these theories probably compre-
hensively explains the complex phenomenon of mucoadhesion 
since it is probably derived from the combination of different 
mechanisms. Therefore, it is preferable to divide the process of 
mucoadhesive bond formation in two main phases. During the first 
phase (or contact stage), the mucoadhesive dosage form wets, 
swells and expands by spreading in the mucus network irregulari-
ties (wetting theory), contributing to the formation of a double layer 
of mechanical interpenetration between the polymer and the mucus 
layer (diffusion theory). The second phase (or consolidation stage) 
is the result of chemical interactions i.e. covalent and ionic bonds, 
hydrogen bonds, electrostatic interactions and van der Waals forces 
between the two substrates (absorption and electronic theory) [49]. 
4.6. Test Methods to Study Mucoadhesion 
 To date, there are no standardized test methods specifically 
designed for the mucoadhesion analysis. Researchers are continuing 
to develop new methods for evaluating the performance of individ-
ual adhesive polymers and/or mucoadhesive properties of different 
dosage forms. However, because of the lack of one or more stan-
dardized techniques, it is difficult to make a direct comparison of 
data obtained by different research groups. So far, most of the in-
formation on bioadhesive materials derived from in vitro methods, 
while in vivo techniques are considered as final tests for those that 
seemed promising as bioadhesives during the initial screening by 
using in vitro techniques [52]. 
 In vitro tests are probably the most common methods for de-
termining the bioadhesive performances. Several techniques cur-
rently in use ranging from simple measurements of the detachment 
force to much more complex experiments have been described in 
the literature. The most common in vitro method to evaluate the 
mucoadhesive potential are reported in Table 1.  
4.7. Factor that Influence Mucoadhesion in the Oral Cavity 
 The mucoadhesion process in the oral cavity is closely related 
both to the molecular features of the bioadhesive polymers and to 
the medium and the environment in which they are inserted. 
 As seen in the previous paragraphs of this paper, saliva and 
mucin are the main biological factors, belonging to the oral cavity 
which may affect, both positively and negatively, the mucoadhe-
sion. 
 The interface between the bioadhesive polymer and the oral 
epithelium is provided by mucus which viscosity, degree of entan-
glement, and water content may affect the bioadhesion process, 
influencing the extent of interaction between the polymer and the 
mucosal substrate. The turnover rate of mucus and the solubility or 
insolubility of the polymers in water determines the residence time 
of the bioadhesive dosage form at the application/absorption site. 
The oral pH may also influence bioadhesion, altering the superficial 
charge of mucus and the ionization of certain adhesive polymers. 
The mechanical stresses, to which the oral tissues are subjected, 
during eating, drinking, talking and swallowing which also continue  
 
involuntarily during the night, reduce the contact time of the dosage 
form with the mucosal surface, and hence affect negatively the 
bioadhesion; these removal forces should be considered during the 
formulation of mucoadhesive dosage forms. Furthermore, it is pos-
sible that tissue modifications induced by certain diseases may 
change the retention bioadhesive properties. 
 The most important polymer-related factors affecting their mu-
coadhesive properties are: molecular weight, chain flexibility, hy-
dration (swelling), hydrogen bonding capacity, cross-linking den-
sity, charge and concentration. 
 The ideal molecular weight to obtain the maxim bioadhesion 
depends on the type of bioadhesive polymer at issue. In fact, the 
same polymer has got a greater or lower bioadhesive strength de-
pending if it is formulated with a high or low molecular weight, 
respectively. Theoretically, the threshold required for successful 
bioadhesion is a molecular weight of about 100,000 KDa. Further-
more, the linear or non-linear polymer structure may influence the 
mucoadhesion. In particular, interpenetration (for lower molecular 
weight polymers) and entanglement (for higher molecular weight 
polymers) are two important features to assess bioadhesiveness of 
linear molecules [52]. 
 It is well known that the first moment of the bioadhesion is the 
diffusion of the polymer chains in the interfacial region. Hence, the 
presence of a certain degree of flexibility of the polymer chains is 
important to obtain an optimal entanglement with the mucus. Mo-
bility and flexibility of the polymer chains is related to their viscosi-
ties and diffusion coefficients; polymers with an higher chain flexi-
bility have a greater diffusion into the mucus network. Furthermore, 
flexibility may improve the hydrogen bonding potential. Finally, it 
is important to underline that when water-soluble polymers become 
cross-linked, mobility of individual polymer chains decrease and 
thus the effective length of the chain that can penetrate into the 
mucus layer decreases, thus reducing the bioadhesive performance. 
 Hydration should be an important feature of mucoadhesive 
polymers that allow them to expand, to create a bioadhesive net-
work, to induce mobility of their chains in order to enhance the 
interpenetration process between polymers and mucin molecules. 
Furthermore, polymer swelling allows mechanical enlargement 
with the consequent exposure of the bioadhesive sites for hydrogen 
bonding and/or electrostatic interaction between the polymer and 
the mucus network.  
 Swelling depends on the polymer concentration, ionic strength, 
as well as the presence of water. Overhydration results in the for-
mation of a wet slippery mucilage without adhesion. 
 Hydrogen bonding capacity is very important for mucoadhe-
sion; polymers with functional groups able to perform hydrogen 
bonds should be preferred. 
 Other three important features of the polymer network which 
must be considered are the average pore number and size, the aver-
age molecular weight of the cross-linked polymers and the density 
of cross-linking. Probably, the degree of hydration and of swelling 
have an inverse correlation with the cross-linking degree of a poly-
mer. In fact, an increased density of the cross-linking cause a diffu-
sion of water in polymer network at a lower rate, with consequent 
reduced swelling and insufficient interpenetration of the polymer in 
the mucus substrate. 
 The molecular charge of the polymers is also important for 
mucoadhesion; in particular, the anionic charge of a polymer is an 
important feature for the mucoadhesive potential. Furthermore, 
some cationic polymers perform good adhesive properties when 
they are in neutral or weakly basic medium. 
 Finally, the polymer concentration is another important factor 
for mucoadhesion, in particular for the possibility of generating 
sufficiently long chains to better penetrate the mucus network and  
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Table 1. In Vitro and In Vivo Techniques to Study Mucoadhesion. Briefly, the Technique Methods and the Main Advantages and 
Disadvantages are Discussed 
IN VITRO METHODS 
Methods Characteristics of the method Advantages and disadvantages 
Tensile (de-
tachment) 
method 
Measurement of the adhesive force between the polymer and biologi-
cal substrate by measuring the force required to break the adhesive 
bond by applying an external tensile stress thanks to an automatic 
tensile machine. The use of a dual tensiometer which allows to con-
sider also the shear forces in evaluating the adhesive bond strength 
has been proposed by some researchers [65, 66]. 
The contact force, the testing speed, the contact time and the 
environment where the adhesion process occurs (e.g. solution 
pH, temperature, concentration of liquid, temperature) influ-
ence the experimental results.  
Results obtained from studies using substrate taken from 
animal tissues are often characterized by poor reproducibility 
due to the variable nature of ex vivo biological substrates. 
Rotating disc 
method 
The technique is based on the use of a rotating stainless steel cylinder 
covered with samples of biological substrate. The dosage forms (tab-
lets, discs or films) are then applied and compressed on the biological 
tissue. The cylinder is then inserted into a dissolution apparatus and 
starts rotating at stable and constant speed and temperature. Every 
change in the position and state of the dosage form are recorded at 
regular intervals until the complete detachment or dissolution of the 
dosage form occurs. 
The time of complete detachment is considered a marker of 
adhesive bond strength and can be used to compare other 
different values, obtained under the same experimental condi-
tions, by using other bioadhesives. It has been shown that 
data obtained by using this method correlate well with those 
obtained by tensile tests for evaluating the adhesive perform-
ance of polymer compounds [68]. 
Flow-through 
method 
This technique is often used to evaluate the mucoadhesive properties 
of micro-, nano- semi liquid-formulations that can not be easily 
evaluated by tensile experiments. It is essential to reproduce in vitro 
as closely as possible the in vivo environmental conditions that occur 
at the mucosal interface, such as temperature, humidity, volume, 
physical features and flow rate of biological fluid. 
This method is useful for evaluating the adhesive perform-
ance of dosage forms that must be administered in body re-
gions where mucosal tissues are subjected to the washing 
effect of biological fluids, such as the gastrointestinal tract, 
the nasal, ocular and vaginal mucosa, and finally the oral 
cavity. 
Rheological 
method 
The mucoadhesion process is evaluated by simulating the interprene-
tration layer by mixing a polymer solution or dispersion with mucin 
solution. The behaviour of mucoadhesive polymer candidates is 
determined by comparing the rheological properties of polymer-
mucin mixture with those of the polymer and mucin separately. 
Polymers with high adhesive performance exhibit a higher viscosity 
in mixtures with mucin when compared to the sum of viscous prop-
erty of the polymer and the mucin considered separately; this 
rheological synergism is considered result of the formation of the 
adhesive bond between polymer and mucus. It has been shown that 
the rheological synergism occurs only within certain polymer concen-
tration ranges and these concentration values depend on the polymer 
under study and on the used substrate.  
The rheological method is a useful approach to allow easy 
and reproducible determination of adhesive properties of a 
polymer. The validity of this method has been reinforced by 
studies that have shown a good correlation of the order rank 
of polymers according to their adhesiveness, by comparing 
data obtained using a rheological approach with those ob-
tained by detachment tensile tests.  
However, results of rheological tests should be always criti-
cally analysed because, since the isolation of freshly isolated 
mucus can be difficult, these tests are often carried out using 
commercially dried mucus which is rehydrated before testing. 
The authors are quite agreed that the rheological properties 
similar to those of freshly isolated mucus can not be obtained 
by using rehydrated mucin gels [148]. 
Fluorescent 
probes 
Measurement of the change in fluorescence by using fluorescent 
probes connected to the mucus substrate when the adhesive polymer 
adheres. The degree of change in fluorescence is proportional to the 
amount of polymer that binds and thus to the adhesive bond strength.  
This technique, based on molecular interactions, allows to 
assess if changes in physical-chemical characteristics of the 
polymer can influence the adhesion process. 
Staining tech-
nique 
Measurement of the relative staining intensity in samples obtained 
after staining with 0.1% Alcian blue or Eosin solution. 
The degree of adhesion of the polymer to the biological sub-
strate is measured by using the relative staining intensity, 
according to the chemical characteristics of the polymer 
[149]. 
Biocore
™
 sys-
tem 
Technique to characterize the molecules according to the specificity 
of their interactions based on the phenomenon of Surface Plasmon 
Reflectance.  
This method allows a quantitative real-time measurement of 
binding between polymer and mucin. 
Methods to 
Study Mucoad-
hesive Interac-
tions 
Infrared, nuclear magnetic resonance and X-ray photoelectron spectroscopy have been recently proposed to study the mucoadhesive 
interactions [49, 52]. 
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(Table 1) Contd.... 
 
IN VITRO METHODS 
Methods Characteristics of the method Advantages and disadvantages 
IN VIVO METHODS 
Gamma scinti-
graphy 
Technique to track the radiolabelled polymers contained in the dosage form 
at the site of application. By means of gamma scintigraphy both the distribu-
tion and retention can be studied. 
Radiolabelled or 
fluorescent dos-
age form 
Measurement of the residence time of fluorescent polymers contained in the 
dosage form at the site of application 
These techniques are less common due to high cost, 
time consuming and ethical factors. But these are 
important to assess the true mucoadhesive potential 
specially in case of oral mucoadhesive drug delivery. 
Magnetic reso-
nance imaging 
technique 
Measurement of the residence time of fluorescent polymers contained in the 
dosage form at the site of application [90]. 
This technique allows to compare the in vivo muco-
adhesive properties of polymer systems candidates 
for oral transmucosal drug delivery [49]. 
 
to create strong adhesive bonds. Very low polymer concentration is 
characterized by smaller number of penetrating polymer chains and 
consequently the interaction between polymer and mucus results 
unstable. Instead, more concentrate polymers determine longer 
penetrating chains and a better adhesion. The highest polymer con-
centrations do not necessarily mean better adhesion; in fact, there is 
an optimal maximum concentration of a bioadhesive polymer to 
produce the better mucoadhesion. However, in highly concentrated 
systems, apart from the optimum concentration level, the adhesive 
strength is significantly reduced because the coiled molecules be-
come separated from the medium so that the chains available for 
interpenetration become limited.  
5. ADHESIVE POLYMERS: IDEAL CHARACTERISTICS 
AND CLASSIFICATION  
 After analysing the polymer-related factors influencing the 
adhesive potential, it is clear what should be the ideal characteris-
tics of a mucoadhesive polymer candidate for insertion in a muco-
adhesive dosage form for oral transmucosal delivery, as listed in 
Table 2. 
 In general, adhesives polymers can be classified: as synthetic, 
natural or semi-natural according to source, as water soluble or 
insoluble according to their solubility, as anionic, cationic or not 
ionic molecules according to their charge, and depending on the 
potential adhesive forces that they generate in contact with the mu-
cus substrate as ionic, covalent, hydrogen bonds or electrostatic 
interactions. Park and Robinson [65] have proposed a classification 
based on adhesion behavior and distinguish three different broad 
categories: 
1) polymers that become sticky when placed in aqueous medium 
and their adhesion depends on this stickiness 
2) polymers that adhere to the mucous layer by means of non-
covalent interactions 
3) polymers that bind to specific receptor sites on cell surface. 
5.1. First Generation Mucoadhesive Polymers 
 Adhesive polymers defined by Lee as the “first generation” 
polymers belong to the first two categories. They lack of specificity 
and targeting ability and bind to the mucus layer by non-specific 
non-covalent interactions (electrostatic interactions, hydrogen and 
hydrophobic bonds) and suffer from short retention times due to the 
rapid rates of mucus turnover. 
 The first generation polymers include: i) anionic polymers, ii) 
cationic polymers, iii) non-ionic polymers and iv) amphoteric 
polymers. Anionic and cationic polymers are those showing the 
greatest mucoadhesive strength [66]. 
 Thanks to their high mucoadhesive properties and low toxicity 
the anionic polymers are widely employed in the formulation of 
several dosage forms. Their negative charge at physiological pH is 
due by the carboxyl and sulphate functional groups. The mucoadhe-
siveness of the polymers belonging to this group is linked to the 
ability of carboxylic groups to form hydrogen bonds with oligosac-
charide chains of mucins. 
 The most important polymers classified in this group are: poly(-
acrylic acid) (PAA) and its weakly cross-linked derivatives, sodium 
carboxymethylcellulose (NaCMC), poly-(methacrylic acid) sodium 
alginate and poly[(maleic acid)-co-(vinyl methyl ether)].  
 Examples of polyacrylic acid-based polymers are carbopol 
(Carbopol®), carbomers, polycarbophil (Noveon
®
), polyacrylate, 
poly(methylvinylether-co-methacrylic) acid, poly(2-hydroxyethyl 
methacrylate), poly(methacrylate), poly(alkylcyanoacrylate), poly 
(isohexylcyanoacrylate), and poly(isobutylcyanoacrylate) [49, 52]. 
 PAA polymers are available in a wide range of molecular 
weights; they are able to form transparent, easily modified gel net-
works and are not irritant, not toxic and are considered safe. 
 Polycarbophil and Carbopol are the more deeply studied PAA-
based polymers as mucoadhesive compounds for drug delivery to 
the gastrointestinal tract, included the oral cavity [67, 68]. The main 
features of polycarbophil are its water-insolubility, its high hydra-
tion or swelling under neutral pH conditions, allowing excellent 
levels of entanglement within the mucus layer. Furthermore, the 
presence of the non-ionized carboxylic acid groups permits the 
creation of hydrogen bonds fundamental to bind the mucosal sur-
faces [66]. 
 In addition to mucoadhesive properties, some anionic polymers 
such as Carbopols exhibit unique gelation behavior, which can be 
easily triggered by changes in solution pH. Hence, the possibility to 
obtain a gel compound (i.e. from a liquid form) and/or to modify 
the gel behaviour of the polymer in relation to variation of the envi-
ronmental pH open excellent opportunities for formulating in situ 
gelling dosage forms allowing a strong bond with mucosal surface 
and a consequent improved dosage form retention times. 
 It is important to underline the existence of a clear distinction 
between carbomer and polycarbophil especially in terms of cross-
linking level and the cross-linking agent itself. Carbomers are 
cross-linked with allyl-sucrose or allyl-pentaerythritol, whereas 
polycarbophil polymers are cross-linked with divinyl glycol. These 
two different cross-linking properties result in a different cross-link 
density and thus in different pharmaceutical and/or cosmetic appli-
cations [49].  
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 Cationic polymers, as chitosan and polymethacrylates, are also 
characterized by optimal mucoadhesive properties [69-71]. Chito-
san is the most abundant polysaccharide in the world, after cellu-
lose, produced by the alkali N-deacetylation of chitin, the main 
constituent of crustacean exoskeletons. Chitosan is a polysaccharide 
with a linear molecular structure of -(1-4)-linked 2-amino-2-
deoxy-D-glucose residues. Its most important physicochemical and 
biological features include: cationic charge, film forming ability, 
antimicrobial and wound healing properties, good biocompatibility, 
favourable toxicological properties, ability to bind lipids and fatty 
acids and to enhance penetration through mucosal membranes [49, 
52]. The high bioadhesive properties of chitosan are related to its 
close interaction with mucins molecules. Whereas PAAs bind to 
mucus via hydrogen bonds, chitosan binds via ionic interactions 
between primary amino functional groups and the sialic acid and 
sulphonic acid substructures of mucins [49, 52]. 
 Although the electrostatic attraction, consisting in the interac-
tion of positively charges of chitosan with negatively charged 
mucins, is the main mechanism for chitosan mucoadhesion, the 
hydrogen bonds (among hydroxyl and amino groups) and hydro-
phobic effects characterize the complex interactions between chito-
san and mucins molecules. The linear structure of chitosan mole-
cules also ensures sufficient chain flexibility for the formation of an 
extensive interpenetration layer. Furthermore, beyond its excellent 
mucoadhesive performances, it may enhance drug absorption via 
paracellular route by the neutralization of fixed anionic sites within 
the tight junctions between mucosal cells [49, 72-74].  
 Thanks to the presence of active functional groups such as 
amines and hydroxyls in its structure, it is possible to obtain several 
derivates (i.e. trimethyl chitosan, glycol chitosan, carboxymethyl-
chitosan and half-acetylated chitosan) from chitosan; however, only 
in few cases their mucoadhesive properties for transmucosal drug 
delivery have been reviewed [52, 75-78]. 
 Non-ionic polymers usually show low bioadhesive properties 
when compared with anionic and cationic molecules. The adhesion 
with mucins is obtained thanks to the diffusion of the macromole-
cules and consequent formation of interpenetration layer with mu-
cus gel [52].  
 Amphoteric polymers or polyampholytes are molecules with 
both cationic and anionic functional groups in their chains. The 
most important polyampholytes with mucoadhesive properties are 
gelatin and N-carboxymethylchitosan. Due to its amphoteric nature 
and self-neutralization of cationic and anionic charged within its 
structure, gelatin has low bioadhesive properties as those of the 
non-ionic polymers. Polyampholytes are characterized by peculiar 
features which must be taken into account when analysing them to 
be used for mucoadhesive and penetration-enhancing purposes. In 
particular, in relation to the pH solution and to their isoelectric 
point, amphoteric polymers may exist in three different states: posi-
tively charged, neutral and negatively charged, with different struc-
tural and physicochemical properties, also affecting mucoadhesive 
and penetration enhancing properties of polyampholyte-based for-
mulations [52]. 
5.2. Second Generation Mucoadhesive Polymers 
 By using first generation non-specific polymer, mucoadhesion 
can occur at any site in addition to that desired for drug release. 
This consideration is particularly important for dosage forms de-
signed for mucoadhesion in the distal gastrointestinal tract. The 
second generation of mucoadhesive polymers is characterized by 
the ability to bind covalently to the mucus layer and adhere directly 
to the cell surface by means of site-specific receptors and covalent 
bonds. Furthermore, this characteristic of some polymers, defined 
as cytoadhesives, makes them less susceptible to mucus turnover 
rates, ensuring that these polymers provide longer retention times. 
Furthermore, a site-specific adhesion through specific receptors 
may trigger intercellular signalling for internalization of drug or 
carrier system by means endocytosis. 
 To this group belong: lectins, bacterial adhesion and thiolated 
polymers or thiomers. 
 The name lectin derives from the Latin word: legere = to select, 
that originally described plant extracts capable of agglutinating red 
blood cells and was found in plants, vertebrates, bacteria, or inver-
tebrates [79]. Today, lectins are naturally occurring glycoproteins 
of a non-immunoglobulin nature that play a fundamental role in 
recognition biological phenomena involving cells and proteins. 
They are capable to recognize specifically and to reversibly bind to 
carbohydrate residues of glucoconjugates complex present on cell 
membrane, without altering the covalent structure of any of the 
recognized glycosyl ligands. As all target-specific polymers, after 
initial mucosal cell-binding, lectins can either remain on the cell 
surface or in the case of receptor-mediated adhesion possibly be-
come internalized via a process of endocytosis. Hence, lectins offer 
three important advantages in drug delivery: they allow the adhe-
sion to a specific target, increase the residence time of the dosage 
form on the mucosal surface and offer a system for controlled de-
livery of macromolecular drug via an active cell-mediated drug 
uptake [49, 80]. However, lectins present several disadvantages: 
Table 2. Ten Important Characteristics of an Ideal Mucoadhesive Polymer 
1. To contain a substantial degree of flexibility in order to achieve the desired entanglement with the mucus [150] 
2. to have a critical molecular weight and an adequate length to allow chain inter-penetration 
3. to have anionic or cationic charges. It has been demonstrated that strong anionic or cationic charge on the polymer provide a greater degree of adhe-
sion compared to non-ionic polymers 
4. to have functional groups able to form hydrogen bonds, which are an important factor in mucoadhesion [151] 
5. to have surface energy properties favouring spreading on a mucus layer [60] 
6. to not irritate the mucosal surface 
7.  to adhere quickly to moist tissue and not to decompose during retention time of dosage forms 
8. to not have high cost, so that the prepared dosage form remains feasible 
9. to allow easy incorporation of the drug and provide drug release in a controlled manner 
10. to demonstrate local enzyme inhibition and penetration enhancement properties 
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many lectins are toxic or immunogenic and may undergo a prema-
ture inactivation by mucus; finally, it is possible that some lectins 
may stimulate lectin-specific antibody production which may block 
lectin-mediate adhesion to the epithelial cell surfaces and to induce 
an anaphylaxis reaction following a subsequent exposure [49, 81]. 
The use of genetically engineered lectins or lectinomimetics com-
pound with reduced toxicity/immunogenicity has been proposed in 
order to ensure mucoadhesive proper performances. 
 The potential adhesive properties of bacterial cells, as a possible 
adhesion system has been object of study in the recent years [12]. 
Bacteria are able to adhere to epithelial surfaces by means of bacte-
rial fimbriae. This latter are long, lectin-like proteins found on the 
surface of many bacterial strains and are strictly linked to bacterial 
pathogenicity. The phenomenon of the adhesion between fimbriae 
and mucosal membranes have been investigated and exploited as a 
means to achieve target-specific drug delivery, to enhance adhesion 
of particular drug carriers or hydrogels to epithelial surfaces. In 
particular, K99-fimbriae, an attachment protein derived from E. 
coli, has been covalently attached to PAA networks, showing a 
better adhesion than controls (unmodified polymers) [82]. 
 Another type of second-generation mucoadhesive polymers are 
thiolated polymers or thiomers. They can be defined as polymers 
containing lateral chains with thiol-bearing functional groups. 
Thiomers are derived from hydrophilic polymers such as polyacry-
lates, chitosan or deacetylated gellan gum which have been conju-
gated with molecules carrying thiol functionality (thiolation proc-
ess). Typical polymers that undergo thiolation are: poly(acrylic 
acid)/cystein, poly(acrylic acid)–homocysteine, chitosan/N-acetyl-
cystein, alginate/cystein, chitosan/thioglycolic acid, chitosan/thio-
ethylamidine, chitosan–iminothiolane, poly(methacrylic acid)–
cysteine, sodium carboxymethylcellulose–cysteine [52, 83-89]. 
 The mucoadhesive properties of thiolated polymers are linked 
to their capability to form covalent bonds (disulfide bridges) with 
cysteine-rich sub-domains of the glycoproteins of the mucus gel 
layer through thiol/disulfide exchange reactions or through a simple 
oxidation of free thiol groups in order to achieved an increased 
residence time and improved bioavailability [49, 52, 90]. With this 
behaviour, they mimic the natural mechanism of mucus glycopro-
teins which are linked to the mucus network through disulphide 
covalent bonds. Thanks to the formation of these bonds with 
mucins molecules thiomers have also enhanced mucoadhesive 
properties in comparison with conventional bioadhesives [91]. Fur-
thermore, the presence of disulphide covalent bonds make thiolated 
polymers less susceptible to modify their behaviour on the basis of 
ionic strength and/or pH changes, when compared with first-
generation mucoadhesive polymers. However, since these kinds of 
bonds may increase rigidity and cross-linking degree, the mecha-
nism of drug release from the delivery system based on thiomers 
could be different [49]. Thiomers have got the capability to bind 
zinc, resulting in the inhibition of aminopeptidases and carboxypep-
tidases, which are zinc dependent proteases. This property is highly 
useful for oral administration of peptide and protein drugs. Finally, 
the thiolation of non-ionic polymers may increase their bioadhe-
siveness opening a new scenario for their use [52]. Recently, the 
potential cytotoxicity of thiolated polymers has been questioned. 
The possible harmful effects on the cell membrane of thiol deriva-
tives of chitosan were evaluated by assessing cell viability and pro-
liferation rate comparing with the unmodified polymer. In fact, 
thiolated compounds have shown a lower cell membrane-damaging 
effect than the unmodified compounds, probably because the thiola-
tion of these polymers determines a greater molecule rigidity due to 
disulfide bridges, resulting in a reduced attachment to the cell 
membrane. However, the cytotoxicity of these compounds is a 
dose-dependent process and occurs at relatively high polymer con-
centrations that should not compromise the use of these polymers 
for the formulation of transmucosal dosage forms. 
5.3. Other Mucoadhesive Polymers 
 Other polymers that should be mentioned are: polymers with 
acrylate end groups, dendrimers copolimers, boronic acid copoly-
mers, synthetic glycopolymers, hydrogels and milk protein. 
 Davidovich-Pinhas and Bianco-Peled have recently proposed 
[92, 93] a new class of mucoadhesive polymers capable of forming 
covalent bonds with mucins similarly to polymeric thiomers [52]. 
An example of these polymer is poly(ethylene glycol) diacrylate; 
however, further studies needed to assess mucoadhesive properties 
of various polymers with acrylate and methacrylate groups to prove 
their greater adhesive properties compared to unmodified ana-
logues. 
 Dendrimers are macromolecules with regular and highly bran-
ched three-dimensional structures consisting of a core, branches and 
end-groups. Their structure and properties make them useful as 
vectors for gene delivery, excipients for enhancing aqueous solubil-
ity of poorly-soluble drugs, antimicrobial agents and drug conju-
gates [94, 95]. Until today only few works have been published 
about the use of dendrimers as mucoadhesives. In particular, it has 
been reported the use of poly(amidoamine) (PAMAM) dendrimers 
carrying various functional groups (amino, carboxylate and hy-
droxyl surface groups) for ocular delivery of pilocarpine nitrate and 
tropicamide [96].  
 Copolymers consist in the association of different monomers 
with varied properties. Recent researches focus their attention on 
delivery system containing block copolymers rather than a single 
polymeric system [29]. A block copolymer is obtained when the 
reaction is carried out in a stepwise manner; the results are chains 
with long sequences or block or a monomer alternating with long 
sequences of another one. When these compounds are composed of 
both hydrophilic and hydrophobic monomers, they are called poly-
mer micelle. These micelles enclose drug molecules, protecting 
them from the attack of aqueous medium thanks to the presence of 
hydrophobic monomers. The most common micelle-based systems 
are formed from poly(ethylene oxide)-b-polypropylene-b-poly (eth-
ylene oxide) tri-block network. Furthermore, there are also graft 
copolymers, constituted by entire chains of one kind (e.g. polysty-
rene) with lateral chains of another kind (e.g. polybutadiene), re-
sulting in more resistant compounds [29]. Hence, both kinds of 
copolymers, block and graft, combine the useful properties of their 
constituents as behaving as two-phase systems [29]. 
 Boronic acid copolymers have been recently proposed as a 
novel class of mucoadhesives [97] constituted by water-soluble 
polymers containing phenyl boronate functional groups to form 
complexes with carbohydrates [52]. The Authors demonstrated that 
the copolymers of N-acryloyl-m-aminophenylboronic acidwith N, 
N-dimethylacrylamide are capable to form insoluble complexes 
with porcine stomach mucin. Furthermore, they supposed that these 
mucoadhesive properties could be also used for ocular, nasal and 
buccal drug delivery. However, none of these routes have been 
investigated until today. 
 Glycopolymers are polymers with sugar moieties as pendant 
groups [98]; they present hybrid properties typical for both polysac-
charides and synthetic polymers. The advantages compared to the 
conventional water-soluble polysaccharides derive from the possi-
bility to manipulate their architecture and physicochemical proper-
ties through homo- and copolymerization with monomers of differ-
ent nature. The use of glycopolymers as mucoadhesive compounds 
have been studied by Rathi et al. [49, 52, 99] which synthesized a 
series of novel glycopolymers starting from a free-radical copolym-
erization of N-(2-hydroxypropyl)methacrylamide with various 
sugar-containing monomers such as N-methacryloylglycyl-
glycylgalactosamine, N-methacryloylglycylglycylfucosylamine, N-
methacryloylglycylglycylglucosamine and N methacryloylglycyl-
glycylmannosamine. The presence of copolymers containing fuco-
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sylamine allows selectively adhering to intestinal mucosa with a 
stronger force compared to fucosylamine-free copolymers. 
 Hydrogels are defined as “wet adhesives” because they require 
an adequately wet environment to show their adhesive properties. 
They are constituted by hydrophilic cross-linked polymers and are 
able to absorb and to retain a great amount of water (30%-40%, 
depending on the polymer used) without dissolving themselves. In 
the oral cavity, the saliva represents the dissolution medium; when 
drugs are loaded in these hydrogels and they are inserted in the oral 
cavity, saliva penetrates into the polymer matrix causing a chain 
relaxation with consequent releasing of the drug molecules through 
the spaces or channels within the hydrogel network [29]. 
 Several polymers belong to the large family of hydrogels: poly-
acrylates (carbopol and polycarbophil), ethylene vinyl alcohol, 
polyethylene oxide, poly vinyl alcohol, poly(N-acryloylpyrro-
lidine), polyoxyethylenes, self-cross-linked gelatin, sodium algi-
nate, natural gums like guar gum, karaya gum, and cellulose ethers 
like methyl cellulose, hydroxypropyl cellulose, hydroxy propyl 
methyl cellulose and sodium carboxy methyl cellulose [29]. Wata-
nabe et al. [100] reported on hydrogels formed by the combination 
of natural gums, xantham gum, and locust bean gum, as being ap-
plicable in buccal delivery systems because of its safety, gel 
strength sustained release properties and good feel in the mouth 
[101]. Locust bean gum and xantham gum alone cannot form a 
hydrogel but when a mixture of these gums is dissolved in a neutral 
medium at 90°C and then cooled with ice for 30 min, a clear, strong 
hydrogel is formed, showing only a low mucoadhesion. 
 Finally, milk protein concentrate containing proteins (minimum 
85%) as Prosobel L85, LR85F at concentration of 15%-50% orga-
nized in bioadhesive tablets have showed good bioadhesive proper-
ties [29]. 
5.4. Multifunctional Polymers 
 The formulation of new dosage forms requires the inclusion of 
a large number of additives to carry out complex tasks in a good 
way to release a drug such as adequate solubility of the drug, in-
creasing the permeability of drug across the biological membrane 
the adhesive strength of the dosage form, the inhibition of the en-
zymatic barrier. Therefore, the search for polymeric compounds 
that have multiple functions allows easier creation of dosage forms 
with good features. 
 Some adhesive polymers, such as PAA and its derivates, have a 
proved capability of inhibiting the activity of certain proteolytic 
enzymes. In particular, policarbophil and other carbomers are able 
to inhibit the activity of trypsin because of their strong affinity to 
divalent cations (Ca2+, Zn
2+
), which are universally known as essen-
tial cofactors for the proteolytic activity. The depletion of calcium 
ions, especially at neutral pH, due to the presence of these multi-
functional polymers, leads to the formation of the secondary struc-
ture of trypsin and the autodegradation of the enzyme itself. 
 The inhibition of the enzymatic barrier thanks to these polymers 
is an important factor to consider for the possible transmucosal 
release of macromolecules such as protein and peptide drugs. 
 It has been shown also that several adhesive polymers may also 
affect the permeability of tissues due to the interactions with epithe-
lial cells. The increased permeability, via the paracellular pathway, 
of several drugs in the presence of some mucoadhesive polymers 
has been attributed to the ability of these polymers to determine an 
expansion of the intercellular spaces; in fact, adhesive polymer is 
usually dry and swellable mucoadhesive and since it accumulates 
water, causes the dehydration and shrinking of epithelial cells, 
which ultimately leads to a physical separation of the intercellular 
junctions. In contrast, other bioadhesive polymers show a different 
biological effect on epithelial cell permeability barrier, but the exact 
mechanism of enhancement need to be further clarified. For a de-
tailed description of the mechanisms by which a compound can 
improve the permeability of a tissue see the review by Veuillez et 
coworkers [6] 
 Finally, some polymers such as poloxamer 407, carbopol, 
hyaluronic acid, and xanthum gum have been reported to act as 
phase-change polymers. These polymers have the specific charac-
teristics to change their properties in response to external stimuli 
such as pH, temperature or the presence of ions and other chemical 
compounds and the induced changes in viscosity of these polymers 
can be used to ensure a controlled and sustained drug release from 
dosage forms. 
5.5. Polymers Association and Complexes 
 In order to enhance the intrinsic mucoadhesive properties, the 
mechanical characteristics, to modulate the swelling behaviour and 
to improve the biocompatibility of different mucoadhesive systems 
polymers, transmucosal dosage forms can be composed by combin-
ing different polymers [102-105]. New mucoadhesive materials are 
prepared by the association of pharmaceutical polymers in solid 
state or in solution. Solid state association may be realized through 
mixing of pulverized excipients and their subsequent compression 
into mucoadhesive tablets or discs [30,32,109]. In this case the final 
mucoadhesive properties of the dosage form will depend on the 
strength of specific interactions occurring between components 
upon hydration. When the interactions between the polymers are 
not very strong and do not lead to the formation of insoluble poly-
complexes, the mucoadhesive properties of a dosage form will be 
intermediate between the adhesiveness of each individual compo-
nents. 
 The association of various polymers in a solution with common 
solvents is used to prepare liquid and semi-solid mucoadhesive 
dosage form. Alternatively, solution mixtures may be dried on flat 
surfaces resulting in mucoadhesive polymeric patches, films or 
spray-dried microparticulate formulations. The knowledge of spe-
cific interactions, which occur between polymers in a common 
solvent, is important since insoluble complexes are often formed 
and they may affect the final properties of dosage forms. Further 
considerations of the effects of specific interactions between poly-
mers within a dosage forms on mucoadhesive performances can be 
found in a recent review. 
6. FACTORS TO CONSIDER FOR THE FORMULATION 
DESIGN OF THE MUCOADHESIVE DOSAGE FORMS 
 Other than the physiological aspects (structure of the oral mu-
cosa, turnover of the oral epithelium and its permeability, pres-
ence/thickness/turnover rate of the mucus layer, presence of saliva 
and mechanical stresses within the oral cavity) already widely dis-
cussed in this manuscript, some pathological, pharmacological and 
pharmaceutical considerations must be taken into account while 
designing a mucoadhesive dosage form. 
 As regards the pathological aspects it is clear that many oral 
diseases can alter the thickness of the epithelium with consequent 
alteration of the barrier properties of the oral mucosa, they can in-
fluence saliva and mucus secretions affecting the retention of the 
mucoadhesive system and thus the therapeutic effects [54]. Hence, 
the knowledge of the possible changes in the oral mucosa and the 
oral environment under pathological conditions is important for 
formulating an adequate and effective oral delivery system [12]. 
 From a pharmacological point the design of a transmucosal 
dosage form must consider: a) where the drug should be delivered: 
systematically or locally; b) the scheduled dose regimens; c) the 
target site of action/absorption; d) drug features and e) the site re-
quiring the treatment: teeth, buccal mucosa, periodontal pockets, 
gums and the entire oral cavity in case of a diffuse disease. 
 Other pharmacological considerations are linked to the intrinsic 
features of the drug; its absorption is related to the partition coeffi-
cient (the rate between the concentration of a drug in an oil phase 
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and dose in an aqueous one; hence, it describes its ability to cross 
the cellular membranes) that explains as the liphophilic drugs per-
meate through the transcellular route, whilst the hydrophilic one 
throughout the paracellular one. However, by modifying chemically 
the drug, it is possible to make it more or less penetrable via the 
oral epithelium. For example, if the non-ionized fraction of an ioni-
sable drug is increased, it becomes more penetrable through the 
paracellular route. In other cases, the modification of the environ-
mental pH may change drug charge making it more o less absorb-
able. It is also possible to modify the lipophilicity of a drug by 
means the acylation or alkylation (a mechanism used to add the N-
terminal of the peptidic drug with lipophilic molecules), the conju-
gation with polymers [as polyethyleneglycol, poly(styrene maleic 
acid), copolymer, albumin and dextrans] and the methylation. 
 Pharmaceutical considerations include those factors influencing 
drug release/kinetics and penetration, organoleptic factors, excipi-
ents to avoid enzymatic drug degradation, excipients to enhance 
permeation and finally, the mucoadhesive polymers deeply ana-
lyzed in the manuscript. 
 Drug release and kinetics from a dosage forms is influenced by 
polymer matrix morphology (formulated as macro or nanospheres, 
gel films, extruded shape: cylinder, rod etc.) or by the presence of 
excipients which modulate polymer and drug degradation. Another 
factor influencing the development of dosage forms for trans-
mucosal drug delivery via the oral mucosa is the drug free concen-
tration within the dosage form. For being available for transmucosal 
release, a drug must not only be released from the dosage form but 
also must be in its free form, i.e. not linked to other components of 
the dosage form. The lack of drug available in the transmucosal 
delivery of the device would greatly reduce the bioavailability of 
the drug.  
 The presence inclusion of enzyme inhibitors in the formulation 
is fundamental to avoid the degradation of peptidic drugs. Some 
protease inhibitors used are: aprotinin, bestatin, puromycin and bile 
salts. Because more than one enzyme is implicated in drug degrada-
tion, it is important to combine more enzymatic inhibitors in the 
formulation design. Furthermore, to increase the peptidic drug sta-
bility it is possible to modify its structure (i.e. substituting some 
amino-acids in its structure). 
 A great importance is the addition of chemical permeability 
enhancers in the formulation of the dosage forms. These excipients 
facilitate the permeation of the drug through the oral mucosa. An 
ideal chemical enhancer should be not toxic and not irritating, the 
absorption-enhancing action should be immediate and unidirec-
tional, the effect of permeation enhancer should be reversible and 
the enhancer should be physically compatible with a wide range of 
drugs and pharmaceutical excipients. Finally, it is important to con-
sider that the selection of an enhancer and its efficacy are linked to 
the physicochemical properties of the drug, site of administration 
(because there may be differences in epithelial thickness, lipid 
composition and enzymatic activity the efficacy of an enhancer in 
one site is not the same than in other). 
 The most common classes of permeation enhancers are: chela-
tors (EDTA, citric acid, sodium salicylate, methoxy salicylates), 
surfactants (sodium lauryl sulphate, polyoxyethylene, Polyoxyeth-
ylene-9-laurylether, Polyoxythylene-20-cetylether, Benzalkonium 
chloride, 23-lauryl ether, cetylpyridinium chloride, cetyltrimethyl 
ammonium bromide), bile salts (sodium glycocholate, sodium de-
oxycholate, sodium taurocholate, sodium glycodeoxycholate, so-
dium taurodeoxycholate), fatty acids (oleic acid, capric acid, lauric 
acid, lauric acid/propylene glycol, methyloleate, lysophosphatidyl-
choline, phosphatidylcholine), non-surfactants (unsaturated cyclic 
ureas), inclusion complexes (cyclodextrins), thiolated polymers: 
chitosan-4-thiobutylamide, chitosan-4-thiobutylamide/GSH, chito-
san-cysteine, Poly(acrylic acid)-homocysteine, polycarbophil-
cysteine, polycarbophil-cysteine/GSH, chitosan-4-thioethylamide/ 
GSH, chitosan-4-thioglycholic acid, novel chitosan derivates: 
methyl-pyrrolidone chitosan and the more recent 5-methyl-
pyrrolidone) and others: aprotinin, azone, cyclodextrin, dextran 
sulfate, menthol, polysorbate, sulfoxides, terpenes, cod-liver oil 
extracts, lysalbinic acids and various alkyl glycosides. 
 Chemical permeation enhancers improve drug mucosal absorp-
tion through several mechanisms of action: changing mucus rheol-
ogy (changing mucus viscosity), increasing the fluidity of epithelial 
cell membrane (disturbing intra-cellular lipid packing by interaction 
with either lipid packing or protein components and finally increas-
ing the fluidity of lipid bilayer membrane), acting on the component 
of tight junctions as desmosomes, by overcoming the enzymatic 
barrier (inhibiting peptidases and proteases) and finally, increasing 
the thermodynamic activity of drug (altering the partition coeffi-
cient of a drug). 
7. MUCOADHESIVE DOSAGE FORM FOR ORAL TRANS-
MUCOSAL DRUG DELIVERY 
 Since oral cavity offers many advantages for local or systemic 
drug delivery within/throughout the oral mucosa, the development 
of mucoadhesive dosage forms has been widely exploited in order 
to provide a targeted and controlled drug release profile. Whilst first 
generation bioadhesives have been extensively investigates, espe-
cially for the topic treatment of oral diseases, more recent investiga-
tions have focused on the systemic controlled delivery of drugs, 
especially peptides, proteins and polysaccharides.  
 According to the mechanism by which drug is released from 
delivery device, dosage forms can be classified in the following 
categories: monolithic (or “matrix”) and reservoir type. In the 
monolithic type systems, the drug is uniformly dispersed or dis-
solved in the polymer matrix and drug release is provided by diffu-
sion trough the polymer network. In the reservoir (or membrane 
controlled) systems, a drug reservoir is entrapped between an im-
permeable backing layer and a polymeric membrane which controls 
the drug release rate. The favourite dosage forms are usually the 
membrane-controlled systems because they promote an unidirec-
tional drug release in the site of action and minimize drug leakage 
in the oral cavity. Furthermore, other desirable attributes of a mu-
coadhesive system for oral transmucosal drug delivery are a high 
drug loading capacity, not irritancy, good mucoadhesion and resi-
dence times, smallness and flexibility enough to be acceptable by 
users, tastelessness and sustained drug release [42].  
 Erodible formulations can be useful because they do not require 
system retrieval at the end of application.  
 Mucoadhesive systems include solid dosage forms as adhesive 
tablets, patches and films, semi-solid and liquid dosage forms and 
they will be discussed briefly. These dosage forms have been de-
veloped to treat both local and systemic conditions. 
7.1. Adhesive Tablets  
 Several bioadhesive tablet systems have been the subject of a 
growing interest [103, 106-109] in order to improve bioavailability 
of drug administered across buccal mucosa. Adhesive tablets are 
small, flat and oval with a diameter approximately of 5-8 mm and 
about 2 mm in thickness [44]. In presence of saliva, they adhere to 
the mucosal surface until dissolution and/or drug release is com-
plete. After a short time of presence of tablet in the mouth, patient 
is not jet aware of its presence, allowing to speak, drink and eat 
without discomfort. Adhesive tablets can be applied to different 
sites in the oral cavity, including the palate, the mucosa of the 
cheeks or in any comfortable position between lip and gum in the 
case of patient wearing dentures. Since the amount of drug deliv-
ered is directly proportional to the surface area, the tablet size and 
shape are also important factors to be considered. A common ap-
proach to avoid clearance of the tablet dosage form from the site of 
application is to place it under the upper lip, as recommended for 
the application of Buccasteam®, an adhesive tablet containing the 
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antiemetic prochlorperazine maleate. Recently, mucoadhesive tab-
lets, containing chlorexhidine, were designed to swell and form a 
gel adhering to the mucosa and controlling the drug release into the 
oral cavity [110]. These tablets were developed by direct compres-
sion, containing different amounts of hydroxypropylmethylcellu-
lose (HPMC) and carbomer; changing the amount ratio of these 
excipients in formulations, it is possible easily modulate the muco-
adhesive effect and release of drug. 
 In order to prevent drug loss from the top surface of the dosage 
form, specialized tablets with two layers have been developed. 
They contain a drug-loaded bioadhesive layer and an impermeable 
backing layer to promote unidirectional drug absorption and to 
minimize drug leakage in the oral cavity. In order to achieve unidi-
rectional release with minimal drug loss, drug can released only 
from the face of the tablet in contact with the buccal mucosa and 
other faces are coated with water impermeable hydrophobic sub-
stances (e.g. ethylcellulose, oil). Bi-layered adhesive tablets con-
taining nystatin were designed with a potential use in the treatment 
of oral candidiasis [111]. In a recent study, these tablets were ap-
plied on 5 healthy volunteers’ gum to obtain residence times and 
subjective parameters. Patient comfort and mucoadhesive behaviour 
were found to be satisfactory [112]. In addition, in a large random-
ised trial, miconazole tablets applied once daily was shown to be 
efficient and reduced the need for the repeated applications in the 
treatment of oral candidiasis in HIV-positive patients [113]. Fur-
thermore, new mucoadhesive prolonged release tablet containing 
clobetasol was found to be more effective than clobetasol ointment 
for the management of oral lichen planus [114]. 
 Several investigators [115, 116] have reported the development 
of mucoadhesive drug delivery devices containing a fast-release 
and a controlled-release layer. The fast release layer contains 
poly(vinyl pyrrolidone) (PVP) as the bioadhesive component and is 
designed to adhere to the buccal mucosa and the controlled release 
layer consist of a mixture of PVP and poly(acrylic acid) and is in-
tended to adhere to the gingival mucosa. 
 Different drugs for chronic therapies have been loaded in adhe-
sive tablets, such as propanolol, timolol, metronidazole, carba-
mazepine metoclopramide, morphine sulphate, nitroglycerin and 
codein [117-119]. Peptides, such as insulin, melatonin [120], calci-
tonin and glucagone-like peptide were also loaded in buccal muco-
adhesive tablets [6, 121-123]. The main disadvantage of this buccal 
dosage form is the lack of physical flexibility, leading to high pa-
tient discomfort and poor patient compliance due to the material 
applied to the mucosa, especially for long term therapy and re-
peated use. Furthermore, the tablets should not be moved once in 
position because its separation from mucosal surface causes more 
rapid drug release and the possibility of swallowing the device and 
subsequently its adhesion to the mucosal surface of the oesophagus.  
7.2. Adhesive Patches 
 Laminated patches are a new type of buccal delivery systems, 
promising not only for systemic drug delivery [124, 125]. The first 
step in the development of an adhesive patch is the selection and 
characterization of a polymer with appropriate bioadhesive proper-
ties and drug release control or combined polymers in order to ob-
tain both of these properties [126, 127]. Bioadhesive patches are 
laminates consisting of a polymeric drug-loaded layer, an imperme-
able backing layer to promote unidirectional drug release and, gen-
erally, mucoadhesive components with or without release retardants 
and additives, such as penetration enhancers or enzyme inhibitors 
[128]. Anders et al [129] have investigated a number of polymers 
and different geometries for developing patches for the delivery of 
different peptides. Veillard et al. [130] designed a unidirectional 
buccal patch consisting of three different layers: an impermeable 
backing layer, a rate limiting central membrane containing the drug, 
and a mucoadhesive layer containing bioadhesive polymer polycar-
bophil. This patch was tested in dog buccal mucosa and was shown 
to remain in place for up to 17 hours without any obvious discom-
fort. A similar three-layer patch was designed and tested on hu-
mans, resulting in a in situ placement for up to 15 h regardless of 
eating or drinking [131]. 
 Mucoadhesive patches containing local anaesthetics (Den-
tiPatch™) have been formulated for site-specific drug delivery that 
purportedly maximizes the effect of anaesthetics diffusing into a 
localized mucosal site to reducing pain associated with injections 
[132]. Recently, an in vitro study demonstrated for the first time as 
a bioadhesive patches for dose controlled delivery of imiquimod, an 
immunomodulator may be potentially used for the treatment of 
dysplastic/neoplastic conditions of the oral cavity and cervix, as 
well as the vulva [133]. Different drugs have been loaded in buccal 
patches for local administration, such as diclofenac, tannic and 
boric acids [117]. Moreover, buccal patches for systemic delivery 
of tyrotropin-releasing hormone, octreotide, oxytocin, buserelin, 
calcitonin and leuenkephalin have been studied for chronic thera-
pies [6, 126, 134]. 
 Despite of long manufacturing times and costs, oral patches has 
high flexibility, thus resulting in a long residence time and high 
patient compliance and comfort. Furthermore, they perform a more 
accurate dosing of drug delivery respect other dosage forms, such 
as gels and sprays; finally, patches, thanks to their flexibility and 
good retention time, protect the underlying diseased tissues, thus 
reducing pain and increasing the treatment effectiveness. 
7.3. Adhesive Films or Pellicles 
 Films are the most recently developed dosage form for buccal 
administration. Bioadhesive films are similar to laminated patches 
in term of manufacturing process, advantages and drawbacks. 
Bioadhesive films should be flexible, elastic, and soft, yet ade-
quately strong to withstand breakage due to stress from mouth 
movements. It must also possess good bioadhesive strength in order 
to be retained in the mouth for the desired duration of action. Swel-
ling of film, if it occurs, should not be too extensive in order to 
prevent discomfort. Multi-layer films, comprising two or more 
layers connected with each other, was recently developed. These 
dosage forms, having a thickness of less than 1 mm, do not cause a 
foreign body sensation, thus contributing to increase patient com-
pliance and comfort. The mucoadhesive layer, containing drug 
molecules, is capable of swelling in an aqueous medium, although 
it is insoluble or only poor soluble in such media. Thanks to the 
mixture of two or more polymers, a fast release and slow release 
layers can be obtained. The mucoadhesive layer is connected with a 
backing layer that is mono- or double-layers and which may serve 
as an active substance reservoir [135]. 
 Some of these dosage forms are not completely water soluble 
and could remain in the oral cavity even after therapeutic goal has 
been achieved. In order to reduce patient discomfort due to the not 
erodible support layer which leaves an insoluble residue in the 
mouth, an erodible film composition, containing water-soluble 
polymers, has been introduced [136]. These dosage forms, in which 
instant wettability causes the film to soften immediately after appli-
cation to the mucosal tissue, are characterized by rapid dissolu-
tion/disintegration after the achieved therapeutic effects, thus pre-
venting the patient from experiencing any prolonged adverse feel-
ing in the mouth. Oral adhesive amlexanox pellicles provide a bet-
ter flexibility, leading to a higher compliance and patient comfort, 
in comparison with adhesive tablets during the treatment of recur-
rent oral ulcerations [137]. Moreover, adhesive films have also the 
advantage of providing better residence times than oral gels on the 
mucosa, which are easily washed away and removed by saliva. 
Finally, a polymeric adhesive film is able to protect the wound 
surfaces, thus reducing pain and treating the oral disease more ef-
fectively [138]. The use of buccal films for buccal drug delivery of 
vaccines has been also reported. The buccal mucosa may be a very 
Mucoadhesion for Oral Drug Delivery Current Pharmaceutical Design, 2012, Vol. 18, No. 34    5511 
interesting site for mucosal immunization, allowing for needle-free 
administration of cost-effective vaccines [42].  
7.4. Adhesive Semi-solid Systems (Gels, Ointments) 
 Semi-solid dosage forms, such as gels and ointments, have the 
advantage of easy dispersion throughout the oral mucosa. They 
form an intimate contact with the mucosal membrane and rapidly 
release drug at the absorption site [139]. However, drug dosing 
from semisolid dosage forms may not be as accurate as from tab-
lets, patches, or films. Poor retention time of the gels at the site of 
application has been overcome by using bioadhesive formulations. 
Nevertheless, despite of bioadhesive polymers, residence time of 
gels is small since body fluids such as saliva will quickly wash they 
away from the site of action. For these reasons, they are of limited 
use for drugs with a narrow therapeutic window. Bioadhesive gels 
for application on oral mucosa in the treatment of some oral disease 
have been known for many years. A major application of adhesive 
gels is the local delivery of medicinal agents for the treatment of 
periodontitis, recurrent aphthous stomatitis, radio/chemotherapy-
induced oral mucositis, oral lichen planus, hyposalivation and re-
cently for wound healing. Orabase
®
, a first generation mucoadhe-
sive paste, has been used as barrier protecting the underlying tissues 
in presence of mucosal ulcers. It has been suggested that mucoad-
hesive polymer-based semi-solid dosage forms might be useful for 
periodontitis therapy when incorporated in antimicrobial-containing 
formulations as doxycycline, minocyclyne or metronidazole gels, 
because of their flow property, easy placement with a syringe and 
retention within the periodontal pocket [124], in order to provide a 
controlled local drug release [140, 141]. A low-dose doxycycline in 
a mucoadhesive gel has been demonstrated to reduce pain in the 
treatment of recurrent oral ulcerations [142]. Furthermore, 
hyaluronic acid has been demonstrated to be an essential compound 
during tissue regeneration and wound healing [143]. Bioadhesive 
ointments and lipid microspheres have not been described in the 
literature as extensively as other dosage forms, especially when 
compared to tablets and patches [12, 144].  
7.5. Adhesive Liquid Systems (Sprays, Oral Rinse) 
 Adhesive liquid systems produce a very fine mist, which tends 
to coat the entire oral mucosa, thereby increasing the total surface 
area through which drug molecules can be absorbed. Compositions 
having high mucoadhesion and viscoelasticity, were suggested for 
the treatment of oral mucosal disease thanks to their film-forming 
properties. An ideal adhesive spray system could be able to produce 
sprays patterns of a suitable ovality and particle size, a suitable 
behaviour and to be delivered in an appropriate unit dose volume to 
avoid unintended administration through the gastrointestinal tract 
by swallowing [59]. 
 Bioadhesive liquid systems (oral rinse and sprays) have been 
proposed for the treatment of several oral diseases, such as oral 
lichen planus and other immunologically mediated diseases, aph-
thous ulcerations, oral mucositis, hyposalivation and finally poten-
tially malignant disorders [145]. Recently, a spray compound con-
taining a pool of collagen precursor aminoacids combined with low 
molecular weight sodium hyaluronate has been shown to be very 
effective in the treatment of radio/chemotherapy-induced oral mu-
cositis [146]. The advantages of a such kind of liquid delivery sys-
tems compared with a gel formulation in the treatment of atrophic 
erosive disease associated with severe pain is to allow a better dis-
tribution in the oral cavity. Oral insulin spray has been proposed as 
alternative to the insulin injections. When compared with subcuta-
neous insulin injection, this insulin spray, called Oralin®, clearly 
showed a faster rapid absorption and a comparable metabolic con-
trol in both type 1 and type 2 diabetic patients [147]. 
8. CONCLUSION 
 The safety and efficacy of current treatment regimens could 
find some advantages from the use of transdermal or transmucosal 
administration routes. In particular, the oral mucosa offers a prom-
ising site in terms of easy accessibility, dosage form retentivity, low 
enzyme activity, good drug bioavailability and high patient compli-
ance. The use of adhesive polymers in the formulation of mucoad-
hesive dosage forms, alternatives to the conventional ones, has been 
proposed to improve the contact time between dosage forms and 
mucosal surface, showing a significant improvement in drug 
bioavailability; thus a site-specific targeting can be predicted, moni-
tored, controlled and sustained, ensuring effective systemic treat-
ment regimens and better patient compliance. In addition, mucoad-
hesive dosage forms have been designated also to treat local disor-
ders, to reduce the required doses and minimize side effects that 
may be caused by systemic administration of drugs.  
 The development of transmucosal dosage forms requires the 
knowledge and the evaluation of several parameters such as pa-
rameters related to physiological and pathological features of the 
oral mucosa and environment and parameters related to the intrinsic 
characteristics of the polymers. Researchers are focusing on new 
polymer generation which bond strength is less related to the condi-
tions of the mucus substrate, ensuring high adhesive performances 
in any condition, and on the combining multiple functions in a sin-
gle mucoadhesive compound. The physic-chemical characteristics 
of the drug to be administered and its possible ability to bind the 
dosage form excipients and to pass through spaces within the poly-
mer network must also be considered.  
 In this complex scenario, virtually ideal mucoadhesive dosage 
forms can only be achieved by combining two or more polymers 
with special properties, and manipulating the formulation of strate-
gies such as the inclusion of pH modifiers, enzyme inhibitors, per-
meation enhancers, etc.. 
 To date, oral transmucosal solid, semi-solid and liquid dosage 
forms have been developed for both systemic and topical drug ad-
ministration. The future direction of these delivery systems is the 
possibility to formulate vaccines and to deliver macromolecular 
drugs, such as proteins and peptides, which can not be effectively 
administered by means of the most conventional routes. 
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